Classifications

• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
  • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
  • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
  • C07D235/18—Benzimidazoles; Hydrogenated benzimidazoles with aryl radicals directly attached in position 2
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
  • A61K31/4164—1,3-Diazoles
  • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
  • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P35/00—Antineoplastic agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P35/00—Antineoplastic agents
  • A61P35/02—Antineoplastic agents specific for leukemia
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
  • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
  • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
  • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
  • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
  • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
  • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
  • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
  • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
  • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
  • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
  • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
  • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
  • C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
  • C07D407/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
  • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
  • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
  • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
  • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
  • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
  • C07D487/04—Ortho-condensed systems

Definitions

• the technical domain of the invention is anticancer drugs.
• Chemotherapy together with surgery and radiotherapy, remains one of the most used approaches for the treatment of cancer. Although some tens of anticancer compounds have been approved for clinical use, there is still a constant need for more selective, more effective and less toxic novel therapeutics. Thus there is an ongoing need in the art to optimize anticancer drugs.
• the invention relates to benzoimidazole derivatives having anticancer properties.
• the compounds according to the invention are able to firstly inhibit the protein/protein interactions of the MAP Kinase Erk, leading to inhibition of proliferation, and secondly to induce apoptosis of cancer cells, notably as demonstrated in human cancer cell lines of lung, colon, melanoma, sarcoma and pancreatic cancer cell lines, but not of normal cells.
• the compounds according to the invention are able to inhibit Erk1/2 interaction with MyD88, Erk meaning Extra cellular signal-regulated kinase and MyD88 meaning Myeloid Differentiation primary response gene 88.
• the compounds of the invention are also able to stimulate the immunogenic cell death (ICD) via the display of markers like the immunogenic cell death markers.
• ICD immunogenic cell death
• Secretion of ATP an active process that occurs during ICD, was also induced by the compounds of the invention on the cell membrane notably of mouse lung cells and human colon cells in particular, and of mouse tumor cells.
• the cell death induced by the compounds of the invention is generally accompanied by the exposure of calreticulin (CRT) on the cell membrane notably of mouse lung cells and human colon cells, and of mouse tumor cells.
• CRT calreticulin
• the compounds of the invention are able to induce apoptosis by a mechanism distinct from that of kinase inhibitors.
• the present invention intends to provide new compounds having one or more of the following characteristics: the compounds of the invention are not kinase inhibitors which are known to generally affect multiple molecular targets generating many side effects;
• the compounds of the invention are surprisingly inducers of the immune system
• the compounds of the invention are safe in vivo at efficient doses; the compounds of the invention are less toxic compared to conventional chemotherapy generating less side effects.
• One of the purpose of the invention is to provide compounds of formula (I) or ( ⁇ ) as described below, notably for use as a medicament in cancer treatment, as well as the pharmaceutically acceptable salts thereof, stereoisomers or mixtures of stereoisomers thereof, in any proportions, particularly a mixture of enantiomers, and especially a racemic mixture.
• Another purpose of the invention is to provide a pharmaceutical composition
• a pharmaceutical composition comprising at least one compound of formula (I), ( ⁇ ), (II) or (III) and a pharmaceutically acceptable carrier.
• Another purpose of the invention is to provide a method for inhibiting oncogenesis and/or cancer cell growing through the MyD88/ERK cell pathway, in particular for inhibiting the MyD88/ERK interaction, and/or for stimulating the display of immunogenic cell death (ICD) markers on the cell membrane of cancer cells comprising the administration to a person in need thereof of an effective amount of a compound of formula (A) as described below, or a pharmaceutically acceptable salt thereof, a stereoisomer or mixture of stereoisomers thereof, in any proportions, particularly a mixture of enantiomers, and especially a racemic mixture.
• ICD immunogenic cell death
• halogen refers to a fluorine, chlorine, bromine or iodine atom.
• amino group refers to a group
• (C1 -C6)alkyl refers to a straight or branched monovalent saturated hydrocarbon chain containing from 1 to 6 carbon atoms including, but not limited to, methyl, ethyl, n-propyl, iso-propyl, n- butyl, iso-butyl, sec-butyl, t-butyl, n-pentyl, n-hexyl, and the like.
• (C1 -C6)alkylcarbonyl refers to a
• (C1 -C6)haloalkyl refers to a (C1 -C6)alkyl group as defined above substituted by at least one halogen atom, and preferably by at least one chlorine or fluorine atom. It can be in particular a trifluoromethyl group.
• (C1 -C6)alkoxy refers to a (C1 -
• C6)alkyl group as defined above bound to the molecule via an oxygen atom including, but not limited to, methoxy, ethoxy, n-propoxy, iso-propoxy, n-butoxy, iso-butoxy, sec-butoxy, t-butoxy, n-pentoxy, n-hexoxy, and the like.
• (C1 -C6)alkoxyalkyl refers to (C1 -C6)alkoxy group as defined above bound to the molecule via an alkyl group as defined above including, but not limited to CH 3 -O-(CH 2 )2-
• (C3-C10)cycloalkyl refers to a hydrocarbon ring having 3 to 10 carbon atoms including, but not limited to, cyclopropyl, cyclopentyl, cyclohexyl and the like.
• oxy(C3-C10)cycloalkyl refers to a (C3-C10)cycloalkyl group as defined above substituted by at least one oxygen atom.
• aryl refers to an aromatic hydrocarbon group comprising preferably 6 to 10 carbon atoms and comprising one or more fused rings, such as, for example, a phenyl or naphtyl group.
• it will be a phenyl group.
• aryloxy refers to an aryl group as defined above bound to the molecule via an oxygen atom, including, but not limited to phenoxy (Ph-O).
• aryl-(C1 -C6)alkyl refers to an aryl group as defined above bound to the molecule via a (C1 -C6)alkyl group as defined above.
• an aryl-(C1 -C6)alkyl group is a benzyl group.
• (C1 -C6)alkoxyaryl refers to a (C1 -C6)alkoxy group as defined above bound to the molecule via an aryl group as defined above. In particular, it can be an methoxyphenyl group (CH 3 -O-Ph-).
• aminoaryl refers to an amino group as defined above bound to the molecule via an aryl group as defined above.
• it can be a dimethylaminophenyl group ((CH 3 ) 2 N-Ph-).
• haloaryl refers to an aryl group as defined above substituted by at least one halogen atom, and bound to the molecule via the aryl group.
• it can be a chlorophenyl group (Cl-Ph-).
• oxyaryl refers to an aryl group as defined above substituted by at least one oxygen atom, and bound to the molecule via the aryl group.
• it can be a oxophenyl group (O-Ph-).
• heteroaryl refers to an aromatic group comprising one or several, notably one or two, preferably one, fused hydrocarbon cycles in which one or several, notably one to four, advantageously one or two, carbon atoms each have been replaced with a heteroatom selected from a sulfur atom, an oxygen atom and a nitrogen atom, preferably selected from an oxygen atom and a nitrogen atom, in particular a nitrogen atom.
• (C1 -C6)alkoxyheteroaryl refers to a (C1 -C6)alkoxy group as defined above bound to the molecule via an heteroaryl group as defined above.
• it can be an methoxypyridyl group (CH3-O-pyridyl-).
• (C1 -C6)alkylheteroaryl refers to a (C1 -C6)alkyl group as defined above bound to the molecule via an heteroaryl group as defined above.
• it can be an ethylpyridyl (C 2 H 5 -pyhdyl-).
• aminoheteroaryl refers to an amino group as defined above bound to the molecule via an heteroaryl group as defined above.
• it can be an aminopyridyl group (NH 2 -pyridyl-).
• heterocycle refers to a saturated, unsaturated or aromatic, preferably not aromatic such as saturated, monocycle or polycycle (comprising fused, bridged or spiro rings), preferably monocycle comprising preferably 5 to 10, notably 5 or 6, atoms in each ring(s), in which the atoms of the ring(s) consist of carbon atoms and one or more, advantageously 1 to 4, and more advantageously 1 or 2, heteroatoms, such as a nitrogen, oxygen or sulphur atom, the remainder being carbon atoms.
• a heterocycle can be notably for example thienyl, furanyl, pyrrolyl, pyrrolidinyl, morpholinyl, piperidinyl or piperazinyl, in particular pyrrolidinyl, morpholinyl, piperidinyl or piperazinyl.
• (C1 -C6)alkylcarbonylheterocycle refers to a (C1 -C6)alkyl group bound to a carbonyl group, the carbonyl group being bound to the heterocycle, the (C1 -C6)alkylcarbonylheterocycle is bound to the molecule via the alkyl group.
• pharmaceutically acceptable as used in the present invention is intended to mean what is useful to the preparation of a pharmaceutical composition, and what is generally safe and non toxic, for a pharmaceutical use.
• pharmaceutically acceptable salt is intended to mean, in the framework of the present invention, a salt of a compound which is pharmaceutically acceptable, as defined above, and which possesses the pharmacological activity of the corresponding compound.
• the pharmaceutically acceptable salts comprise:
• organic bases comprise diethanolamine, ethanolamine, N-methylglucamine, triethanolamine, tromethamine and the like.
• Acceptable inorganic bases comprise aluminium hydroxide, calcium hydroxide, potassium hydroxide, sodium carbonate and sodium hydroxide.
• stereoisomers refers to configurational stereoisomers and includes geometric isomers and optical isomers.
• optical isomers result from the different position in space of substituents or lone pair of electrons on an atom (such as a carbon or sulphur atom) comprising four different substituents (including potentially a lone pair of electron). This atom thus represents a chiral or asymmetric center.
• Optical isomers which are not mirror images of one another are thus designated as “diastereoisomers,” and optical isomers which are non-superimposable mirror images are designated as "enantiomers”.
• racemate An equimolar mixture of two enantiomers of a chiral compound is designated as racemate or racemic mixture.
• compound of formula (I) as used in the present invention includes a compound of formula (la), (lb), (lc) or (Id).
• compound of formula ( ⁇ ) as used in the present invention includes a compound of formula (I'a), (I'b), (I'c), (I'd) or (I'e).
• compound of formula (II) as used in the present invention includes a compound of formula (I la) or (Mb).
• compound of formula (III) as used in the present invention includes a compound of formula (Ilia) or (1Mb).
• the figures 1 , 2 and 3 show the induction of apoptosis in HCT1 16 cells treated with compound 2, 6 and 7 respectively.
• Figure 1 represents the fold induction of caspas activity in ordinate and the concentration of compound 2 in ⁇ , from left to right 1 ⁇ , 1 .78 ⁇ , 3.16 ⁇ . 5,62 ⁇ , 10 ⁇ , 17.8 ⁇ and 31 .6 ⁇ in abscissa.
• Figure 2 represents the fold induction of caspas activity in ordinate and the concentration of compound 6 in ⁇ , from left to right 1 ⁇ , 1 .45 ⁇ , 2.1 1 ⁇ , 3.08 ⁇ , 4.47 ⁇ , 6.5 ⁇ , 9.46 ⁇ , 13.8 ⁇ and 20 ⁇ in abscissa.
• Figure 3 represents the fold induction of caspas activity in ordinate and the concentration of compound 7 in ⁇ , from left to right 1 ⁇ , 5 ⁇ , 10 ⁇ , 20 ⁇ , 35 ⁇ and 50 ⁇ in abscissa.
• the figure 4 shows the xenograft results on mice treated with compound 6 or vehicle.
• Figure 4 represents the tumor volume in ordinate and the concentration of compound 6 in mg/kg from left to right 50 mg/kg, 25 mg/kg and 12.5 mg/kg.
• the invention relates to a compound of formula (I) below for use as a medicament in a cancer treatment, or a pharmaceutically acceptable salt thereof, a stereoisomer or mixture of stereoisomers thereof, in any proportions, particularly a mixture of enantiomers, and especially a racemic mixture,
• Xi , X2 and X3 represent, independently of one another, a carbon atom or a nitrogen atom;
• n 0 or 1 ;
• R 1 represents H, (C1 -C6)alkyl or halogen
• R 2 represents H, COOH, (C1 - C6)alkyl, (C1 -C6)haloalkyl, nitrile (CN), aryl, arylcarbonyl, heteroaryl, CONR1 1 R12, NR13R14, 0-(C1 -C6)alkyl or SO 2 NR15R16, COR17; with
• R1 1 represents H or (C1 -C6)alkyl
• R12 represents H, (C1 -C6)alkyl, aryl, heteroaryl, (C1 -C6)alkoxyheteroaryl, (C1 -C6)alkoxyaryl, haloaryl, (C1 -C6)alkoxyalkyl, (C1 -C6)alkylheteroaryl, aminoaryl or aryl-(C1 -C6)alkyl;
• R13 represents H or CH 3 ;
• R14 represents H, CH 3 , (C1 -C6)alkyl, (C1 -C6)alkylcarbonyl, arylcarbonyl, or heteroarylcarbonyl;
• R15 represents CH 3 ;
• R16 represents CH 3 ;
• R17 represents (C1 -C6)alkyl, aryl, heteroaryl, (C1 -C6)alkoxyheteroaryl, (C1 -C6)alkoxyaryl, haloaryl, (C1 -C6)alkoxyalkyl, (C1 -C6)alkylheteroaryl, aminoaryl, (C1 -C6)alkoxyalkyl or aryl-(C1 -C6)alkyl;
• R 3 represents H, (C1 -C6)alkyl or halogen
• ⁇ R 4 represents H, CI, CN, NO 2 , NHR18 or OR19 with
• R18 represents H, (C1 -C6)alkyl, aryl, heteroaryl or (C1 -C6)alkylcarbonyl ;
• R19 represents H or (C1 -C6)alkyl;
• R 5 represents H, aryl, heteroaryl, heterocycle, aminoheteroaryl, aminoaryl, (C1 -C6)alkylcarbonyl, arylcarbonyl, (C1 -C6)alkylheteroaryl, heteroarylcarbonyl, (C1 - C6)alkoxyarylcarbonyl, oxyaryl, OR20 or NR21 R22 with
• R20 represents H, (C1 -C6)alkyl, aryl, heterocycle, (C1 - C6)alkylcarbonylheterocycle or heteroaryl;
• R21 represents H or (C1 -C6)alkyl, aryl, heteroaryl, (C1 -C6)alkyl-N((C1 -
• C6)alkyl 2 , (C1 -C6)alkyl-NH(C1 -C6)alkyl, heteroarylcarbonyl, COR23, (C1 - C6)alkylcarbonyl, arylcarbonyl or heteroarylcarbonyl;
• R22 represents H, (C1 -C6)alkyl, aryl, heteroaryl, (C1 -C6)alkyl-N((C1 - C6)alkyl) 2 , (C1 -C6)alkyl-NH(C1 -C6)alkyl, heteroarylcarbonyl, (C1 - C6)alkyl heteroaryl, COR23, (C1 -C6)alkylcarbonyl, arylcarbonyl or heteroarylcarbonyl ;
• R21 and R22 bring together, represent (C3-C10)cycloalkyl or oxy(C3- C10)cycloalkyl;
• R23 represents (C1 -C6)alkyl, aryl, heteroaryl, (C1 -C6)alkylheteroaryl, (C1 - C6)alkoxyaryl or (C1 -C6)alkyloxyaryl;
• R 6 represents H, OH, CH3, (C1 - C6)alkoxy or (C1 -C6)alkyl
• R 6 represents a (C1 -C6)alkanoic acid amide where the nitrogen atom is substituted by R24 and R25, with R24 and R25 represents independently H, (C1 -C6)alkyl, aryl, heteroaryl, heterocycle, (C1 -C6)alkoxyaryl, (C1 - C6)alkoxyheteroaryl, (C1 -C6)alkylcarbonylaryl or (C1 -
• R 7 represents H, N or CH 3 ;
• R 7 represents H or CH 3 then R 10 and R 8 does not exist ;
• R 10 when R 7 represents N, then R 10 exists and represents a carbon atom, a double bond exists between R 7 and R 10 , a single bond exists between R 10 and R 9 , a single bond exists between R 10 and R 8 and R 8 represents H, (C1 -C6)alkyl, halogen;
• R 9 is a carbon atom.
• the formula (I) is the formula (la) below:
• the formula (I) is the formula (lb) below:
• the formula (I) is the formula (lc) below:
• the formula (I) is the formula (Id) below:
• the invention relates to a compound of formula ( ⁇ ) below for use as a medicament in a cancer treatment, or a pharmaceutically acceptable salt thereof, a stereoisomer or mixture of stereoisomers thereof, in any proportions, particularly a mixture of enantiomers, and especially a racemic mixture,
• Xi represents N or CR 2 , preferably CR 2 ;
• X 2 represents N or CR 5 , preferably CR 5 ;
• R 1 represents H, (C1 -C6)alkyl or halogen, preferably H; • R 2 represents H; CN; a (C1 -C6)alkyl group optionally substituted with one or several halogen atoms (such as F); an aryl or heteroaryl group optionally substituted with one or more groups selected from halo, (C1 -C6)alkyl, OR32 and NR33R34; CONR1 1 R12 or COR17; wherein
• R1 1 represents H or (C1 -C6)alkyl
• R12 represents a (C1 -C6)alkyl, aryl, aryl-(C1 -C6)alkyl or 5- or 6-membered heteroaryl group optionally substituted with one or more groups selected from halo, (C1 -C6)alkyl, OR35 and NR36R37;
• R17 represents a (C1 -C6)alkyl, aryl, aryl-(C1 -C6)alkyl or heteroaryl group optionally substituted with one or more groups selected from halo, (C1 - C6)alkyl, OR38 and NR39R40;
• R32, R33, R34, R35, R36, R37, R38, R39, and R40 represent, independently of one another, H or (C1 -C6)alkyl
• R 3 represents H, (C1 -C6)alkyl or halogen, preferably H;
• R 4 represents H, CI, CN, NO 2 , NHR18 or OR19, preferably H, wherein:
• R18 represents H, (C1 -C6)alkyl, aryl, heteroaryl or (C1 -C6)alkylcarbonyl;
• R19 represents H or (C1 -C6)alkyl;
• R 5 represents NR21 R22 wherein:
• R21 represents H, R41 or COR41 ;
• R22 represents H, R42 or COR42
• R21 and R22 form together with the nitrogen atom bearing them a heterocycle, preferably a saturated heterocycle, optionally substituted with a (C1 -C6)alkyl group;
• R41 and R42 represent, independently of one another, a (C1 -C6)alkyl, aryl, aryl-(C1 -C6)alkyl or heteroaryl group optionally substituted with one or more groups selected from halo, (C1 -C6)alkyl, OR43 and NR44R45;
• R43, R44 and R45 represent, independently of one another, H or (C1 -
• R 6 represents H, OH, (C1 -C6)alkoxy or (C1 -C6)alkyl, preferably H;
• R 7 represents H or (C1 -C6)alkyl, preferably H;
• R21 represents H or R32 and R22 represents H or R33 or R21 and R22 form together with the nitrogen atom bearing them a heterocycle, preferably a saturated heterocycle, optionally substituted with a (C1 - C6)alkyl group.
• the formula ( ⁇ ) is the formula (I'a) below:
• the formula ( ⁇ ) is the formula (I'b) below:
• the formula ( ⁇ ) is the formula (I'c) below:
• the formula ( ⁇ ) is the formula (I'd) below:
• the formula ( ⁇ ) is the formula (I'e) below:
• R 1 is H or (C1 -C6)alkyl, such as H or CH 3 , preferably H.
• X 1 is a carbon atom for the compounds of formula (I) or CR 2 for the compounds of formula ( ⁇ ).
• R 2 is CN.
• R 2 is H or a (C1 -C6)alkyl group optionally substituted with one or several halogen atoms such as F.
• R 2 can be more particularly H or CF 3 .
• R 2 is an aryl or heteroaryl group optionally substituted with one or more groups selected from halo, (C1 -C6)alkyl, OR32 and NR33R34.
• it is a heteroaryl group optionally substituted with one or more groups selected from halo, (C1 -C6)alkyl, OR32 and NR33R34.
• the heteroaryl group is preferably a 5- or 6-membered heteroaryl, such as a 6-membered heteroaryl, e.g. pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl, or triazinyl and more particularly pyrimidinyl.
• R 2 can be a pyrimidinyl group.
• R 2 is COR17.
• R17 represents an aryl, or heteroaryl group, preferably an aryl group, such as a phenyl, optionally substituted with one or more groups selected from halo, (C1 -C6)alkyl, OR38 and NR39R40.
• R17 can be a phenyl.
• R 2 is CONR1 1 R12, notably with
• R1 1 representing H or (C1 -C6)alkyl, such as H or CH 3 , preferably H;
• R12 representing a (C1 -C6)alkyl, aryl, or 5- or 6-membered heteroaryl group optionally substituted with one or more groups selected from halo, (C1 -C6)alkyl, OR35 and NR36R37; such as (C1 -C6)alkyl, aryl, heteroaryl, (C1 -C6)alkoxyheteroaryl, (C1 -C6)alkoxyaryl, haloaryl, (C1 - C6)alkoxyalkyl, (C1 -C6)alkylheteroaryl, aminoaryl or aryl-(C1 -C6)alkyl.
• R 2 is CONR1 1 R12 with R1 1 representing H or (C1 -C6)alkyl, such as H or CH 3 , preferably H, and R12 representing an aryl, or 5- or 6- membered heteroaryl group optionally substituted with one or more groups selected from halo, (C1 -C6)alkyl, OR35 and NR36R37; such as aryl, heteroaryl, (C1 -C6)alkoxyheteroaryl, (C1 -C6)alkoxyaryl, haloaryl, (C1 -C6)alkoxyalkyl, (C1 - C6)alkylheteroaryl, aminoaryl or aryl-(C1 -C6)alkyl.
• R1 1 representing H or (C1 -C6)alkyl, such as H or CH 3 , preferably H
• R12 representing an aryl, or 5- or 6- membered heteroaryl group optionally substituted with one or more groups selected from halo,
• the aryl can be a phenyl and the 5- or 6-membered heteroaryl group can be furyl, thienyl, pyrrolyl, pyridyl, oxazolyl, isoxazolyl, thiazolyle, isothiazolyl, imidazolyl, pyrazolyl, oxadiazolyl, thiadiazolyl, triazolyl, tetrazolyl, pyridazinyl, pyrimidinyl, pyrazinyl, or triazinyl.
• the 5- or 6-membered heteroaryl group is a 6-membered heteroaryl group such as pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl, or triazinyl, preferably a pyridyl.
• R 2 is CONR1 1 R12 with R1 1 representing H or (C1 -C6)alkyl, such as H or CH 3 , preferably H, and R12 representing a 5- or 6-membered heteroaryl group optionally substituted with one or more groups selected from halo, (C1 -C6)alkyl, OR35 and NR36R37; such as a (C1 -C6)alkoxyheteroaryl, (C1 - C6)alkylheteroaryl or heteroaryl.
• the 5- or 6-membered heteroaryl group can be furyl, thienyl, pyrrolyl, pyridyl, oxazolyl, isoxazolyl, thiazolyle, isothiazolyl, imidazolyl, pyrazolyl, oxadiazolyl, thiadiazolyl, triazolyl, tetrazolyl, pyridazinyl, pyrimidinyl, pyrazinyl, or triazinyl.
• the 5- or 6-membered heteroaryl group is a 6-mennbered heteroaryl group such as pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl, or triazinyl, preferably a pyridyl.
• R 2 is CONR1 1 R12 with R1 1 representing H or CH 3 , and R12 representing a pyridyl, an alkoxylpyridyl group or an ethylpyridyl.
• R 3 is H, CI or CH 3 , such as H or CH 3 , preferably H.
• y represents a carbon atom and n is equal to 1 , the remaining other chemical groups of the compound of formula (I) are as defined above, including their variants.
• X 3 is a carbon atom, the remaining other chemical groups of the compounds of formula (I) are as defined above, including their variants.
• X 2 is a carbon atom, the remaining other chemical groups of the compounds of formula (I) are as defined above, including their variants.
• R 5 represents NR21 R22 with
• R22 representing H, (C1 -C6)alkyl, aryl, heteroaryl, (C1 -C6)alkyl-N((C1 - C6)alkyl) 2 , (C1 -C6)alkyl-NH(C1 -C6)alkyl, heteroarylcarbonyl, COR23, (C1 -C6)alkylcarbonyl, arylcarbonyl or heteroarylcarbonyl.
• R 5 represents NR21 R22 with R21 representing H or (C1 - C6)alkyl, preferably H, and R22 representing COR42.
• R42 represents an aryl or heteroaryl group optionally substituted with one or more groups selected from halo, (C1 -C6)alkyl, OR43 and NR44R45.
• the aryl is a phenyl and the heteroaryl is a 5- or 6-membered heteroaryl, more particularly a 5-membered heteroaryl, such as furyl, thienyl, pyrrolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, imidazolyl, pyrazolyl, oxadiazolyl, thiadiazolyl, triazolyl, or tetrazolyl; in particular furyl, pyrrolyl, oxazolyl, isoxazolyl, imidazolyl, pyrazolyl, oxadiazolyl (such as 1 ,3,5-oxadiazolyl), triazolyl, or tetrazolyl.
• a 5-membered heteroaryl such as furyl, thienyl, pyrrolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl
• R 5 represents NR21 R22 with R21 representing H or R41 and R22 representing H or R42 or R21 and R22 form together with the nitrogen atom bearing them a heterocycle, preferably a saturated heterocycle, optionally substituted with a (C1 -C6)alkyl group.
• R 5 represents NR21 R22 with R21 representing H or R41 and R22 representing H or R42.
• R41 and R42 represent, independently of one another, a (C1 -C6)alkyl group.
• the heterocycle is advantageously a saturated 5- or 6-membered heterocycle, such as pyrrolidinyl, morpholinyl, piperidinyl or piperazinyl.
• R 5 represents NR21 R22 with R21 and R22 each representing, independently of one another, H, or (C1 -C6)alkyl, such as H or CH 3 .
• R 6 represents H or (C1 -C6)alkyl, such as H or CH 3 , preferably H.
• R 4 represents H, or (C1 -C6)alkyl, such as H or CH 3 , preferably H.
• R 7 represents H or CH 3 , preferably H.
• R 7 represents H or CH 3 , in particular H, and R 10 and R 8 do not exist, the remaining other chemical groups of the compound of formula (I) are as defined above, including their variants.
• R 7 represents H, R 10 and R 8 do not exist, X 2 and X 3 are carbon atoms, R 6 is H and R 5 represents NR21 R22 with
• R21 represents H or (C1 -C6)alkyl
• R22 represents H, (C1 -C6)alkyl, aryl, heteroaryl, (C1 -C6)alkyl-N((C1 - C6)alkyl) 2 , (C1 -C6)alkyl-NH(C1 -C6)alkyl, heteroarylcarbonyl, COR23, (C1 -C6)alkylcarbonyl, arylcarbonyl or heteroarylcarbonyl;
• R 7 represents H
• R 10 and R 8 do not exist
• X 2 and X 3 are carbon atoms
• R 6 is H
• R 5 represents NR21 R22 with
• R21 represents H or CH 3 ;
• - R22 represents H, or CH 3 ;
• any one of the above described embodiments can be combined together, with any one of another embodiment of the list.
• R 1 represents H
• R 2 represents CONR1 1 R12
• X 1 is a carbon atom
• n is 1
• R 3 represents H and y is a carbon atom
• the remaining other chemical groups of the compound of formula (I) are as defined above, including their variants.
• R 2 is CONR1 1 R12 with R1 1 representing H or (C1 -C6)alkyl, such as H or CH 3 , preferably H, and R12 representing a 5- or 6-membered heteroaryl group optionally substituted with one or more groups selected from halo, (C1 - C6)alkyl, OR35 and NR36R37; and
• R 5 is NR21 R22 with R21 representing H or R41 and R22 representing H or R42 or R21 and R22 form together with the nitrogen atom bearing them a heterocycle, preferably a saturated heterocycle, optionally substituted with a
• R 2 is CONR1 1 R12 with R1 1 representing H or (C1 -C6)alkyl, such as H or CH 3 , preferably H, and R12 representing a 5- or 6-membered heteroaryl group optionally substituted with one or more groups selected from halo, (C1 - C6)alkyl, OR35 and NR36R37; and R 5 is NR21 R22 with R21 representing H or R41 and R22 representing H or R42.
• R 2 is CONR1 1 R12 with R1 1 representing H or (C1 -C6)alkyl, such as H or CH 3 , preferably H, and R12 representing a 5- or 6-membered heteroaryl group optionally substituted with one or more groups selected from halo, (C1 - C6)alkyl, OR35 and NR36R37; and
• R 5 is NR21 R22 with R21 and R22 each representing, independently of one another, H, or (C1 -C6)alkyl, such as H or CH 3 .
• R 2 is CONR1 1 R12 with R1 1 representing H and R12 representing a pyridyl group optionally substituted with one or more groups selected from halo, (C1 - C6)alkyl, OR35 and NR36R37; and
• R 5 is NR21 R22 with R21 and R22 each representing, independently of one another, H, or (C1 -C6)alkyl, such as H or CH 3 .
• R 1 , R 3 , R 4 , R 6 and R 7 each represent advantageously H.
• the 5- or 6-membered heteroaryl group can be furyl, thienyl, pyrrolyl, pyridyl, oxazolyl, isoxazolyl, thiazolyle, isothiazolyl, imidazolyl, pyrazolyl, oxadiazolyl, thiadiazolyl, triazolyl, tetrazolyl, pyridazinyl, pyrimidinyl, pyrazinyl, or triazinyl.
• the 5- or 6- membered heteroaryl group is a 6-membered heteroaryl group such as pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl, or triazinyl, preferably a pyridyl.
• the compound of formula (I) or ( ⁇ ) is chosen among compounds 1 to 46, preferably compounds 1 to 3, 5 to 10, 12 to 16, 19, 24 to 26, 28 to 35, 37, 38, 40 to 42, 45 and 46, as disclosed in the examples and the pharmaceutically acceptable salts thereof.
• the compound of formula (I) or ( ) is chosen among compounds
• the invention also relates to a method of treatment of cancer comprising the administration of an effective amount of a compound of formula (I) or ( ⁇ ) or any one of its embodiments disclosed above to a person in need thereof.
• the invention also relates to the use of a compound of formula (I) or ( ⁇ ) or any one of its embodiments disclosed above for the manufacture of a medicament for the treatment of cancer.
• the cancer to be treated will be advantageously lung cancer, colon cancer, colorectal cancer head and neck cancer, prostate cancer, breast cancer, ovarian cancer, cervical cancer, leukemia, lymphoid cancer, skin cancer, pancreatic cancer, intestinal cancer, liver cancer, bladder cancer, esophageal cancer, gastric cancer, male genital cancer, mesothelioma, sarcoma or bone cancer.
• the present invention relates also to a method for inhibiting oncogenesis and/or cancer cell growing through the MyD88/ERK cell pathway, in particular for inhibiting the MyD88/ERK interaction, and/or for stimulating the display of immunogenic cell death (ICD) markers on the cell membrane of cancer cells
• Xi represents N or CR 2 , preferably CR 2 ;
• X2 represents N or CR 5 , preferably CR 5 , when represents a double bond, or CHR 5 , preferably CH 2 , when represents a single bond;
• X3 represents CR 6 when represents a double bond, or NR 6a when represents a single bond;
• R 1 represents H, (C1 -C6)alkyl or halogen, preferably H;
• R 2 represents H; CN; a (C1 -C6)alkyl group optionally substituted with one or several halogen atoms (such as F); an aryl or heteroaryl group optionally substituted with one or more groups selected from halo, (C1 -C6)alkyl,
• R1 1 represents H or (C1 -C6)alkyl
• R12 represents H or a (C1 -C6)alkyl, aryl, aryl-(C1 -C6)alkyl or heteroaryl group optionally substituted with one or more groups selected from halo, (C1 -C6)alkyl, OR35 and NR36R37;
• R17 represents a (C1 -C6)alkyl, aryl, aryl-(C1 -C6)alkyl or heteroaryl group optionally substituted with one or more groups selected from halo, (C1 - C6)alkyl, OR38 and NR39R40;
• R32, R33, R34, R35, R36, R37, R38, R39, and R40 represent, independently of one another, H or (C1 -C6)alkyl
• R 3 represents H, (C1 -C6)alkyl or halogen, preferably H;
• R 4 represents H, CI, CN, NO 2 , NHR18 or OR19, preferably H, wherein:
• R18 represents H, (C1 -C6)alkyl, aryl, heteroaryl or (C1 -C6)alkylcarbonyl;
• R19 represents H or (C1 -C6)alkyl
• R 5 represents H, R46, COR46, OR20 or NR21 R22, preferably NR21 R22, wherein:
• R20 represents H or a (C1 -C6)alkyl, aryl, aryl-(C1 -C6)alkyl or heteroaryl group optionally substituted with one or more groups selected from halo, (C1 -C6)alkyl, OR47, NR48R49 and COR50;
• R21 represents H, R41 or COR41 ;
• R22 represents H, R42 or COR42
• R21 and R22 form together with the nitrogen atom bearing them a heterocycle, preferably a saturated heterocycle, optionally substituted with a (C1 -C6)alkyl group;
• R41 and R42 represent, independently of one another, a (C1 -C6)alkyl, aryl, aryl-(C1 -C6)alkyl or heteroaryl group optionally substituted with one or more groups selected from halo, (C1 -C6)alkyl, OR43 and NR44R45;
• R46 represents a (C1 -C6)alkyl, aryl, aryl-(C1 -C6)alkyl or heteroaryl group, preferably a heteroaryl group, optionally substituted with one or more groups selected from halo, (C1 -C6)alkyl, OR51 and NR52R53;
• R43, R44, R45, R47, R48, R49, R51 , R52 and R53 represent, independently of one another, H or (C1 -C6)alkyl
• R50 represents a (C1 -C6)alkyl, aryl, heterocycle or heteroaryl group, preferably a heterocycle group, optionally substituted with one or more groups selected from halo and (C1 -C6)alkyl;
• R 6 represents H, OH, (C1 -C6)alkoxy or (C1 -C6)alkyl, preferably H;
• R 6a represents a (C1 -C6)alkyl substituted with one CONHR54 group wherein:
• R54 represents a (C1 -C6)alkyl, aryl, aryl-(C1 -C6)alkyl, heterocycle or heteroaryl group, preferably a heterocycle group, optionally substituted with one or more groups selected from halo, (C1 -C6)alkyl, OR55, NR56R57 and COR58;
• R55, R56 and R57 represent, independently of one another, H or (C1 - C6)alkyl
• R58 represents a (C1 -C6)alkyl
• R 7 represents H or (C1 -C6)alkyl, preferably H.
• R 1 is H or (C1 -C6)alkyl, such as H or CH 3 , preferably H.
• X 1 is CR 2 .
• R 2 is CN
• R 2 is H or a (C1 -C6)alkyl group optionally substituted with one or several halogen atoms such as F.
• R 2 can be more particularly H or CF 3 .
• R 2 is NR1 1 COR12.
• R1 1 represents H or (C1 - C6)alkyl, such as H or CH 3 , preferably H
• R12 represents an aryl or heteroaryl group, preferably a heteroaryl group, optionally substituted with one or more groups selected from halo, (C1 -C6)alkyl, OR35 and NR36R37.
• the aryl can be a phenyl and the heteroaryl can be a 5- or 6-membered heteroaryl group such as furyl, thienyl, pyrrolyl, pyridyl, oxazolyl, isoxazolyl, thiazolyle, isothiazolyl, imidazolyl, pyrazolyl, oxadiazolyl, thiadiazolyl, triazolyl, tetrazolyl, pyridazinyl, pyrimidinyl, pyrazinyl, or triazinyl.
• R 2 is an aryl or heteroaryl group optionally substituted with one or more groups selected from halo, (C1 -C6)alkyl, OR32 and NR33R34.
• it is a heteroaryl group optionally substituted with one or more groups selected from halo, (C1 -C6)alkyl, OR32 and NR33R34.
• the heteroaryl group is preferably a 5- or 6-membered heteroaryl, such as a 6-membered heteroaryl, e.g. pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl, or triazinyl and more particularly pyrimidinyl.
• R 2 can be a pyrimidinyl group.
• R 2 is COR17.
• R17 represents an aryl, or heteroaryl group, preferably an aryl group, such as a phenyl, optionally substituted with one or more groups selected from halo, (C1 -C6)alkyl, OR38 and NR39R40.
• R17 can be a phenyl.
• R 2 is COOR1 1 or CONR1 1 R12, preferably CONR1 1 R12.
• R1 1 represents H or (C1 -C6)alkyl, such as H or CH 3 , preferably H
• R12 represents an aryl or heteroaryl group, preferably a heteroaryl group, optionally substituted with one or more groups selected from halo, (C1 -C6)alkyl, OR35 and NR36R37.
• the aryl can be a phenyl and the heteroaryl can be a 5- or 6-membered heteroaryl group such as furyl, thienyl, pyrrolyl, pyridyl, oxazolyl, isoxazolyl, thiazolyle, isothiazolyl, imidazolyl, pyrazolyl, oxadiazolyl, thiadiazolyl, triazolyl, tetrazolyl, pyridazinyl, pyrimidinyl, pyrazinyl, or triazinyl.
• the heteroaryl group is a 6-membered heteroaryl group such as pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl, or triazinyl, preferably a pyridyl.
• R 3 is H, CI or CH 3 , such as H or CH 3 , preferably H.
• R 4 represents H, or (C1 -C6)alkyl, such as H or CH 3 , preferably H.
• X 2 is CR 5 .
• R 5 represents NR21 R22.
• R 5 represents NR21 R22 with R21 representing H or (C1 -C6)alkyl, preferably H, and R22 representing COR42.
• R42 represents an aryl or heteroaryl group optionally substituted with one or more groups selected from halo, (C1 -C6)alkyl, OR43 and NR44R45.
• the aryl is a phenyl and the heteroaryl is a 5- or 6-membered heteroaryl, more particularly a 5-membered heteroaryl, such as furyl, thienyl, pyrrolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, imidazolyl, pyrazolyl, oxadiazolyl, thiadiazolyl, triazolyl, or tetrazolyl; in particular furyl, pyrrolyl, oxazolyl, isoxazolyl, imidazolyl, pyrazolyl, oxadiazolyl (such as 1 ,3,5-oxadiazolyl), triazolyl, or tetrazolyl.
• a 5-membered heteroaryl such as furyl, thienyl, pyrrolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl
• R 5 represents NR21 R22 with R21 representing H or R41 and R22 representing H or R42 or R21 and R22 form together with the nitrogen atom bearing them a heterocycle, preferably a saturated heterocycle, optionally substituted with a (C1 -C6)alkyl group.
• R 5 represents NR21 R22 with R21 representing H or R41 and R22 representing H or R42.
• R41 and R42 represent, independently of one another, a (C1 -C6)alkyl group.
• the heterocycle is advantageously a saturated 5- or 6-membered heterocycle, such as pyrrolidinyl, morpholinyl, piperidinyl or piperazinyl.
• R 5 represents NR21 R22 with R21 and R22 each representing, independently of one another, H, or (C1 -C6)alkyl, such as H or CH 3 .
• X 3 is CR 6 .
• R 6 represents H or (C1 -C6)alkyl, such as H or CH 3 , preferably H.
• R 7 represents H or CH 3 , preferably H.
• R 1 , R 3 , R 4 , R 6 and R 7 each represent advantageously H.
• any one of the above described embodiments can be combined together, with any one of another embodiment of the list.
• the compound of formula (A) can be in particular a compound of formula ( ⁇ ) as defined above according to any one of its embodiments disclosed above.
• the compound of formula (A) is chosen among compounds 1 to 46, preferably compounds 2, 6 and 7, as disclosed in the examples and the pharmaceutically acceptable salts thereof.
• the invention relates also to a pharmaceutical composition
• a pharmaceutical composition comprising at least one compound of formula (I) or ( ⁇ ) as defined above according to any one of their embodiments and a pharmaceutically acceptable carrier.
• the invention relates also to a pharmaceutical composition
• a pharmaceutical composition comprising at least one compound of formula (II) or (III) as defined below according to any one of their embodiments and a pharmaceutically acceptable carrier.
• the invention relates also to a pharmaceutical composition
• a pharmaceutical composition comprising at least one compound of formula (I) or ( ⁇ ) as defined above according to any one of their embodiments, said compound of formula (I) or ( ⁇ ) being linked to an antibody, advantageously via a linker, in order to form an ADC.
• the invention relates also to a pharmaceutical composition
• a pharmaceutical composition comprising at least one compound of formula (II) or (III) as defined below according to any one of their embodiments, said compound of formula (II) or (III) being linked to an antibody, advantageously via a linker, in order to form an ADC.
• compositions according to the invention may be formulated for parenteral (for example subcutaneous, intraperitoneal, intramuscular, intravenous, intracranial, intrathecal, etc.), oral, sublingual, transdermal, local or rectal administration, intended for mammals, including humans.
• parenteral for example subcutaneous, intraperitoneal, intramuscular, intravenous, intracranial, intrathecal, etc.
• oral, sublingual, transdermal, local or rectal administration intended for mammals, including humans.
• the dosage varies according to the treatment and according to the condition in question.
• the active ingredient can be administered in the form of administration units, mixed with conventional pharmaceutical carriers, to animals or human beings.
• Appropriate oral administration unit forms include tablets, gels, powders, granules, and oral solutions or suspensions, and parenteral administration forms, notably intraperitoneal.
• the main active ingredient is mixed with a pharmaceutical carrier such as gelatin, starch, lactose, magnesium stearate, talc, gum arabic, or the like.
• a pharmaceutical carrier such as gelatin, starch, lactose, magnesium stearate, talc, gum arabic, or the like.
• the tablets can be coated with sucrose or other appropriate materials or even be treated so that they have an extended or delayed activity and that they continuously release a predetermined quantity of active ingredient.
• a capsule preparation is obtained by mixing the active ingredient with a diluent and pouring the mixture obtained into hard or soft capsules.
• a preparation in the form of a syrup or elixir can contain the active ingredient conjointly with a sweetener, an antiseptic and an appropriate taste enhancer and dye.
• Powders or granules dispersible in water can contain the active ingredient in mixture with dispersing or wetting agents or suspending agents, and with flavor correctors or sweeteners.
• aqueous suspensions, isotonic saline solutions or sterile and injectable solutions are used that contain pharmacologically- compatible dispersing agents and/or wetting agents.
• the active ingredient can also be formulated in the form of microcapsules, possibly with one or more additional carriers.
• the pharmaceutical composition according to the invention further comprises at least one antitumour drug different from the compound of formula (I) or ( ) or (II) or (III), as combined preparation for a simultaneous, separate or sequential use in the treatment of mammals, in particular humans, suffering from a cancer such as a malignant (cancerous) tumour.
• the pharmaceutical composition according to the invention further comprises at least one of the following antitumour drugs and/or targeted therapies, without being limited to this list: abraxane, abarelix, aldesleukin, alemtuzumab, alitretinoin, allopurinol, altretamine, anastrozole, arsenic trioxide, asparaginase, azacitidine, atezolizumab, bevacizumab, bexarotene, bicalutamide, bleomycin, bortezomib, intravenous busulphan, oral busulphan, calusterone, capecitabine, carboplatin, carmustine, cetuximab, chlorambucil, cisplatin, cladribine, clofarabine, cyclophosphamide, cytarabine, dacarbazine, dactinomycin, dalteparin sodium, dasatinib, daunorubi
• compositions according to the present invention are useful in the treatment of cancer, notably as defined above.
• the invention relates also to a compound of formula (II) below:
• Xi , X2 and X3 represents, independently of one another, a carbon atom or a nitrogen atom;
• n 0 or 1 ;
• R 1 represents H, (C1 -C6)alkyl or halogen
• R 2 represents H, COOH, (C1 - C6)alkyl, (C1 -C6)haloalkyl, nitrile, aryl, heteroaryl, arylcarbonyl, CONR1 1 R12, NR13R14, 0-(C1 -C6)alkyl or SO 2 NR15R16, COR17; with
• R1 1 represents H or (C1 -C6)alkyl
• R12 represents H, (C1 -C6)alkyl, aryl, heteroaryl, (C1 -C6)alkoxyheteroaryl, (C1 -C6)alkoxyaryl, haloaryl, (C1 -C6)alkoxyalkyl, (C1 -C6)alkylheteroaryl, aminoaryl or aryl-(C1 -C6)alkyl;
• R13 represents H or CH 3 ;
• R14 represents H, CH 3 , (C1 -C6)alkyl, (C1 -C6)alkylcarbonyl, aryloxycarbonyl, or heteroarylcarbonyl ;
• R15 represents CH 3 ;
• R16 represents CH 3 ;
• R17 represents (C1 -C6)alkyl, aryl, heteroaryl, (C1 -C6)alkoxyheteroaryl, (C1 -C6)alkoxyaryl, haloaryl, (C1 -C6)alkoxyalkyl, (C1 -C6)alkylheteroaryl, aminoaryl, (C1 -C6)alkoxyalkyl or aryl-(C1 -C6)alkyl;
• R 3 represents H, (C1 -C6)alkyl or halogen
• R 4 represents H, CI, CN, NO 2 , NHR18 or OR19 with R18 represents H, (C1 -C6)alkyl, aryl, heteroaryl or (C1 -C6)alkylcarbonyl ; R19 represents H or (C1 -C6)alkyl;
• R 5 represents aryl, heteroaryl, heterocycle, aminoheteroaryl, aminoaryl, (C1 -C6)alkylheteroaryl, (C1 -
• R20 represents H, (C1 -C6)alkyl, aryl, heterocycle, (C1 -
• R21 represents H or (C1 -C6)alkyl
• R22 represents H, (C1 -C6)alkyl, aryl, heteroaryl, (C1 -C6)alkyl-N((C1 -
• R21 and R22 represents together a (C3-C10)cycloalkyl or a oxy(C3-
• R23 represents (C1 -C6)alkyl, aryl, heteroaryl, (C1 -C6)alkylheteroaryl, (C1 - C6)alkoxyaryl or (C1 -C6)alkyloxyaryl;
• R 6 represents H, OH, CH 3 , (C1 - C6)alkoxy or (C1 -C6)alkyl
• R 6 represents a (C1 -C6)alkanoic acid amide where the nitrogen atom is substituted by R24 and R25, with R24 and R25 represents independently H, (C1 -C6)alkyl, aryl, heteroaryl or heterocycle ;
• R 7 represents H, N or CH 3 .
• the formula (II) is the formula (I la) below:
• the formula (II) is the formula (Mb) below:
• R 1 is H or CH 3 , the remaining other chemical groups of the compound of formula (II) are as defined above, including their variants.
• Xi is a carbon atom
• the remaining other chemical groups of the compound of formula (II) are as defined above, including their variants.
• R 2 is CONR1 1 R12 with
• R1 1 representing H or (C1 -C6)alkyl
• R12 representing H, (C1 -C6)alkyl, aryl, heteroaryl, (C1 - C6)alkoxyheteroaryl, (C1 -C6)alkoxyaryl, haloaryl, (C1 -C6)alkoxyalkyl,
• R 2 is CONR1 1 R12 with R1 1 represents H or CH 3 , and R12 represents a (C1 -C6)alkoxyheteroaryl, (C1 -C6)alkylheteroaryl or heteroaryl, the remaining other chemical groups of the compound of formula (II) are as defined above, including their variants.
• R 2 is CONR1 1 R12 with R1 1 represents H or CH 3 , and R12 represents a pyridil, an alkoxylpyridil group or an ethylpyridyl, the remaining other chemical groups of the compound of formula (II) are as defined above, including their variants.
• R 3 is H or CH 3 , the remaining other chemical groups, of the compound of formula (II) are as defined above including their variants.
• y represents a carbon atom and n is equal to 1 , the remaining other chemical groups of the compound of formula (II) are as defined above, including their variants.
• R 7 represents H or CH 3 , the remaining other chemical groups of the compound of formula (II) are as defined above, including their variants.
• X 3 is a carbon atom, the remaining other chemical groups of the compound of formula (II) are as defined above, including their variants.
• X 2 is a carbon atom, the remaining other chemical groups of the compound of formula (II), are as defined above including their variants.
• R 5 represents NR21 R22 with
• R21 representing H or (C1 -C6)alkyl
• R22 representing H, (C1 -C6)alkyl, aryl, heteroaryl, (C1 -C6)alkyl-N((C1 - C6)alkyl) 2 , (C1 -C6)alkyl-NH(C1 -C6)alkyl, heteroarylcarbonyl, COR23, (C1 -C6)alkylcarbonyl, aryloxycarbonyl or heteroarylcarbonyl ; and - the remaining other chemical groups of the compound of formula (II) being as defined above, including their variants.
• R 5 represents NR21 R22 with R21 and R22 each represent, independently of one another, H, or (C1 -C6)alkyl, such as H or CH 3 , the remaining other chemical groups of the compound of formula (II) are as defined above, including their variants.
• R 6 represents H, or (C1 -C6)alkyl, such as H or CH 3 , the remaining other chemical groups of the compound of formula (II) are as defined above, including their variants.
• R 4 represents H, or (C1 -C6)alkyl, such as H or CH 3 , the remaining other chemical groups of the compound of formula (II) are as defined above, including their variants.
• R 7 represents H, X 2 and X 3 are carbon atoms, R 6 is H and R 5 represents NR21 R22 with
• R21 representing H or (C1 -C6)alkyl
• R22 representing H, (C1 -C6)alkyl, aryl, heteroaryl, (C1 -C6)alkyl-N((C1 - C6)alkyl) 2 , (C1 -C6)alkyl-NH(C1 -C6)alkyl, heteroarylcarbonyl, COR23,
• R 7 represents H
• R 10 and R 8 does not exist
• X 2 and X 3 are carbon atoms
• R 6 is H
• R 5 represents NR21 R22 with
• R21 representing H, or (C1 -C6)alkyl, such as H or CH 3 ;
• R22 representing H, or (C1 -C6)alkyl, such as H or CH 3 ;
• the compounds of formula (II) may notably be chosen from among compounds 1 to 46, such as compounds 1 to 3, 5 to 10, 12 to 16, 19, 24 to 26, 28 to 35, 37, 38, 40 to 42, 45 and 46, preferably compounds 2, 6, and 7, disclosed in the examples and the pharmaceutically acceptable salts thereof.
• the invention relates also to a compound of formula (III) below
• Xi , X2 and X3 represent a carbon atom
• R 1 represents H
• R 2 represents H, CH 3 , CF 3 , CN, COOH, (C1 -C6)alkyl, (C1 -C6)alkylcarbonyl, aryloxycarbonyl, heteroarylcarbonyl, nitrile, aryl, heteroaryl, arylcarbonyl, CONR26R27 or NR28R29; with
• R26 representing H or CH 3 ;
• R27 representing H, (C1 -C6)alkyl, aryl, heteroaryl, (C1 -C6)alkoxyheteroaryl, (C1 -C6)alkoxyaryl, haloaryl, (C1 -C6)alkoxyalkyl, (C1 -C6)alkylheteroaryl, aminoaryl or aryl-(C1 -C6)alkyl;
• R28 representing H or CH 3 ;
• R29 representing H, CH 3 , (C1 -C6)alkyl, (C1 -C6)alkylcarbonyl, aryloxycarbonyl or heteroarylcarbonyl;
• R 3 represents H
• R 4 represents H
• R 5 represents NR30R31 with R30 and R31 represent H or (C1 -C6)alkyl
• R 6 represents H or CH 3 .
• the formula (III) is the formula (1Mb) below:
• R 2 represents CONR26R27 with
• R26 representing H or CH 3 ;
• R27 representing H, (C1 -C6)alkyl, aryl, heteroaryl, (C1 - C6)alkoxyheteroaryl, (C1 -C6)alkoxyaryl, haloaryl, (C1 -C6)alkoxyalkyl, (C1 -C6)alkylheteroaryl, aminoaryl or aryl-(C1 -C6)alkyl; and
• R 2 represents CONR26R27 with
• R27 representing heteroaryl, (C1 -C6)alkoxyheteroaryl, (C1 - C6)alkoxyaryl;
• the invention relates also to a compound of formula ( ) as defined above according to any one of its embodiments disclosed above.
• compounds of formula (I), ( ⁇ ) (II) or (III) may notably be chosen from among compounds 1 to 44, such as compounds 1 to 3, 5 to 10, 12 to 16, 19, 24 to 26, 28 to 35, 37, 38, and 40 to 42, preferably compounds 2, 6, and 7, as disclosed in the examples and the pharmaceutically acceptable salts thereof.
• the compounds of the present invention can be prepared according to the synthetic routes outlined in Schemes 1 , 2 and 3 below and by the following methods described therein.
• Benzoimidazoles of Formula I as defined on scheme 1 may be prepared in a multi-step sequence from 3,4-diamino-benzoic acid ethyl ester i and an appropriately substituted aldehyde iia with a reagent such as NaHSO3 or Na 2 S 2 O 5 and for some compounds without reagents.
• the benzoimidazoles of Formula iii may be prepared from 3,4-diamino-benzoic acid ethyl ester i and an appropriately substituted carboxylic acid iib with a reagent such as polyphosphoric acid. Saponification of iii and amidation of the resulting carboxylic acid iv with an appropriately substituted amine v with a coupling reagent such as EDCI or HATU produces benzoimidazoles of Formula I.
• Benzoimidazoles of Formula II as defined on scheme 2 may be prepared in a multi-step sequence from 2-(4-nitro-phenyl)-3H- benzoimidazole-5-carboxylic acid ethyl ester iiib.
• the reduction of the nitro group provides the corresponding 2-(4- amino-phenyl)-3H- benzoimidazole-5-carboxylic acid ethyl ester vi which may be substituted with the appropriately substituted carboxylic acid vii.
• the amide viii may be hydrolyzed to the carboxylic acid ix and may reacts with the appropriately substituted amine v and a coupling reagent to produce benzoimidazoles of Formula II.
• the 2-(4-nitro-phenyl)-3H- benzoimidazole-5-carboxylic acid ethyl ester iiib may be hydrolyzed to the corresponding 2-(4-nitro-phenyl)-3H- benzoimidazole-5-carboxylic acid ivb which can react with the appropriately substituted amine v to give the amide x.
• Reduction of the nitro derivative x and coupling of the resulting amine with the appropriately substituted carboxylic acid vii and a coupling reagent produces benzoimidazoles of Formula II.
• Benzoimidazoles of Formula III as defined on scheme 3 may be prepared in a multi-step sequence from 3,4-diamino-benzamide xiia, or from (3,4-diamino- phenyl)-phenyl-methanone xiib, or from 3,4-diamino-benzonitrile xiic, or from 3,5- dimethylbenzene-1 ,2-diamine xiid, or from 5-chloro-3-methylbenzene-1 ,2-diamine xiie, or from 4-Pyrimidin-2-yl-benzene-1 ,2-diamine xiif, or from 4-nitro-benzene- 1 ,2-diamine xiig, or from 4-(trifluoromethyl)benzene-1 ,2-diamine xiih, and an appropriately substituted aldehyde iia with a reagent such as NaHSO3 or Na2S2O 5 .
• benzoimidazoles of Formula III may be prepared from 3,4-diamino- benzamide xiia, or from (3,4-diamino-phenyl)-phenyl-methanone xiib, or from 3,4- diamino-benzonitrile xiic, or from 3, 5-dimethyl-benzene-1 ,2-diamine xiid, or from 5-chloro-3-methyl-benzene-1 ,2-diamine xiie, or from 4-Pyrimidin-2-yl-benzene- 1,2-diamine xiif, or from 4-nitro-benzene-1 ,2-diamine xiig, or from 4- (trifluoromethyl)benzene-1,2-diamine xiih, and an appropriately substituted carboxylic acid iib with a reagent such as polyphosphoric acid.
• a reagent such as polyphosphoric acid
• HATU 1-[Bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3- oxid hexafluorophosphate
• Step 7 Preparation of 3,4-diamino-benzoic acid ethyl ester i
• Step 4 2-(4-dimethylamino-phenyl)-1 H-benzoimidazole-5-carboxylic acid (3- methoxy-phenyl)-amide
• the solid obtained was purified by column chromatography using silica gel 230-400 in DCM/methanol solvent system.
• the product obtained was further purified by recrystallization from methanol to obtain 2-(4-dimethylamino- phenyl)-1 H-benzoimidazole-5-carboxylic acid (3-methoxy-phenyl)-amide as an off- white solid (92 mg, 36 % yield).
• 2-(4-Dimethylamino-phenyl)-1 H-benzoimidazole-5-carboxylic acid pyridin-4- ylamide was synthesized from 2-(4-dimethylamino-phenyl)-1 H-benzoimidazole-5- carboxylic acid and pyridin-4-ylamine by following the procedure for example 1 .
• 2-(4-Dimethylamino-phenyl)-1 H-benzoimidazole-5-carboxylic acid (2-methoxy- ethyl)-amide was synthesized from 2-(4-dimethylamino-phenyl)-1 H- benzoimidazole-5-carboxylic acid and 2-methoxy-ethylamine by following the procedure for example 1 .
• Step 7 2-(4-dimethylamino-phenyl)-1 H-benzoimidazole-5-carboxylic acid ethyl ester
• Step 2 2-(4-Dimethylamino-phenyl)-1 H-benzoimidazole-5-carboxylic acid
• 2-(4-dimethylamino-phenyl)-1 H-benzoimidazole-5- carboxylic acid ethyl ester 2.445 g, 7.9 mmol, 1 .00 eq
• THF 25ml
• LiOH H 2 O 1g, 24.5 mmol, 3.12 eq
• dimethylamino-phenyl)-amide was prepared using 2-(4-dimethylamino-phenyl)-1 benzoimidazole-5-carboxylic acid and N,N-dimethylbenzene-1 ,4-diamine DMF/CH 2 CI 2 1 :1 by following the procedure for example 6.
• 2-pyridin-4-yl-3H-benzoimidazole-5-carboxylic acid ethyl ester was prepared using 3,4-diamino-benzoic acid ethyl ester i and pyridine-4-carbaldehyde in DMF following the procedure for example 1 .
• 2-pyridin-4-yl-3H-benzoimidazole-5-carboxylic acid was prepared from 2-pyridin-4- yl-3H-benzoimidazole-5-carboxylic acid ethyl ester by following the procedure for example 1 .
• 2-Pyridin-4-yl-1 H-benzoimidazole-5-carboxylic acid dimethylamide was prepared from 2-pyridin-4-yl-3H-benzoimidazole-5-carboxylic acid and ⁇ , ⁇ -dimethylamine in THF (1 M) following the procedure for example 1 .
• 2-Pyridin-4-yl-3H-benzoimidazole-5-carboxylic acid was solubilized in N,N- dimethylformamide at a 0.1 M concentration with 2 equivalents of diisopropylethylamine.
• the coupling reagent O-(Benzotriazol-1 -yl)-N,N,N',N'- tetramethyluronium tetrafluoroborate (TBTU) was solubilized at 0.1 M in N,N- dimethylformamide.
• TBTU tetramethyluronium tetrafluoroborate
• Benzothiazol-6-ylamine was solubilized in ⁇ , ⁇ -dimethylformamide at a 0.1 M.
• 2-Pyridin-4-yl-3H- benzoimidazole-5-carboxylic acid methyl-phenyl-amide was prepared using 2-pyridin-4-yl-3H- benzoimidazole-5-carboxylic acid and N- methylaniline by following the procedure for example 1 .
• Step 7 2-(4-nitro-phenyl)-3H- benzoimidazole-5-carboxylic acid ethyl ester iiib
• 2-(4-nitro-phenyl)-3H- benzoimidazole-5-carboxylic acid methyl ester iiib was prepared using 4-nitro-benzaldehyde and 3,4-diamino-benzoic acid ethyl ester i by following the procedure for example 1 .
• Step 2 2-(4-amino-phenyl)-3H- benzoimidazole-5-carboxylic acid ethyl ester vi
• 2-(4-nitro-phenyl)-3H- benzoimidazole-5-carboxylic acid ethyl ester iiib 500 mg, 1 .61 mmol
• Pd/C 10 %, 50% wet
• the reaction was monitored by TLC.
• reaction mass was filtered through celite® bed and the filtrate concentrated to get the crude product which further purified using flash column chromatography with silica (230- 400) and methanol/CH 2 Cl 2 (2-3%) as eluent to obtain pure 2-(4-amino-phenyl)-3H- benzoimidazole-5-carboxylic acid methyl ester vi (270 mg, 59 % yield). MS m/z (M+H) 282.4.
• Step 3 2- ⁇ 4-[(1 -Methyl-1 H-pyrrole-2-carbonyl)-amino]-phenyl ⁇ -1 H- benzoimidazole-5-carboxylic acid ethyl ester
• Step 4 2- ⁇ 4-[(1 -Methyl-1 H-pyrrole-2-carbonyl)-amino]-phenyl ⁇ -1 H- benzoimidazole-5-carboxylic acid
• 2- ⁇ 4-[(1 -Methyl-1 H-pyrrole-2-carbonyl)-amino]-phenyl ⁇ -1 H- benzoimidazole-5- carboxylic acid was prepared from 2- ⁇ 4-[(1 -Methyl-1 H-pyrrole-2-carbonyl)-amino]- phenyl ⁇ -1 H- benzoimidazole-5-carboxylic acid ethyl ester by following the procedure for example 1 .
• Step 5 2- ⁇ 4-[(1 -Methyl-1 H-pyrrole-2-carbonyl)-amino]-phenyl ⁇ -1 H- benzoimidazole-5-carboxylic acid phenylamide
• reaction mixture from above was added to crushed ice, filtered, and the solid obtained purified by column chromatography using silica gel 230-400 in CH 2 Cl 2 /methanol solvent system.
• the product obtained was further purified by recrystallization from methanol to obtain 2- ⁇ 4-[(1 -Methyl-1 H-pyrrole-2-carbonyl)- amino]-phenyl ⁇ -1 H- benzoimidazole-5-carboxylic acid phenylamide as an off white solid (1 10 mg, 36 % yield).
• Step 1 2-(4-nitro-phenyl)-3H- benzoimidazole-5-carboxylic acid ethyl ester iiib
• 2-(4-nitro-phenyl)-3H- benzoimidazole-5-carboxylic acid methyl ester was prepared using 4-nitro-benzaldehyde and 3,4-diamino-benzoic acid methyl ester by following the procedure for example 1 .
• Step 2 2-(4-nitro-phenyl)-3H- benzoimidazole-5-carboxylic acid ivb
• 2-(4-nitro-phenyl)-3H- benzoimidazole-5-carboxylic acid ivb was prepared from 2- (4-nitro-phenyl)-3H- benzoimidazole-5-carboxylic acid ethyl ester by following the procedure for example 1 .
• MS m/z (M+H) 312.1 was prepared from 2- (4-nitro-phenyl)-3H- benzoimidazole-5-carboxylic acid ethyl ester
• Step 3 2-(4-nitro-phenyl)-3H- benzoimidazole-5-carboxylic acid phenylamide
• 2-(4-nitro-phenyl)-3H- benzoimidazole-5-carboxylic acid phenylamide was prepared using 2-(4-nitro-phenyl)-3H- benzoimidazole-5-carboxylic acid and aniline by following the procedure for example 13.
• MS m/z (M+H) 359.1 was prepared using 2-(4-nitro-phenyl)-3H- benzoimidazole-5-carboxylic acid and aniline by following the procedure for example 13.
• Step 4 2-(4-amino-phenyl)-3H- benzoimidazole-5-carboxylic acid phenylamide was prepared from 2-(4-nitro-phenyl)-3H- benzoimidazole-5-carboxylic acid phenylamide by following the procedure for example 13. MS m/z (M+H) 329.4.
• Step 5 2- ⁇ 4-[(Oxazole-5-carbonyl)-amino]-phenyl ⁇ -1 H- benzoimidazole-5- carboxylic acid phenylamide
• Step 7 2-(4-nitro-phenyl)-3H- benzoimidazole-5-carboxylic acid methyl-phenyl- annide
• Step 2 2-(4-amino-phenyl)-3H- benzoimidazole-5-carboxylic acid methyl-phenyl- amide
• 2-(4-amino-phenyl)-3H- benzoimidazole-5-carboxylic acid methyl-phenyl-amide was prepared from 2-(4-nitro-phenyl)-3H- benzoimidazole-5-carboxylic acid methyl-phenyl-amide by using the procedure for example 13.
• MS m/z (M+H) 343.1 MS m/z (M+H) 343.1 .
• Step 3 2- ⁇ 4-[(Furan-3-carbonyl)-amino]-phenyl ⁇ -1 H- benzoimidazole-5-carboxylic acid methyl-phenyl-amide
• Step 7 2-(4-nitro-phenyl)-3H- benzoimidazole-5-carboxylic acid (3-methoxy- phenyl)-amide
• Step 2 2-(4-Amino-phenyl)-1 H- benzoimidazole-5-carboxylic acid (3-methoxy- phenyl)-amide
• Step 7 2-(4-Nitro-phenyl)-3H-benzoimidazole-5-carboxylic acid amide
• Step 2 2-(4-Amino-phenyl)-1 H- benzoimidazole-5-carboxylic acid amide
• 2-(4-Dimethylamino-phenyl)-1 H-benzoimidazole-5-carboxylic acid (4-chloro- phenyl)-amide was prepared using 2-(4-dimethylamino-phenyl)-1 H- benzoimidazole-5-carboxylic acid and 4-chloroaniline by following the procedure for example 6.
• Step 7 2-(3-Hydroxy-phenyl)-1 H-benzoimidazole-5-carboxylic acid 3,4-Diamino-benzoic acid (0.76 g, 5 mmol) was dissolved in 15 ml_ of N,N- dimethylformannide and one equivalent of 3-hydroxy-benzaldehyde (0.61 g, 5 mmol) was added. The solution was heated to 80 °C for 5 hours and cooled to room temperature. The precipitate was filtered, washed with methanol and used without further purification (Yield 60%).
• Step 2 2-(3-Hydroxy-phenyl)-1 H- benzoimidazole-5-carboxylic acid phenethyl- amide
• 2-(3-Hydroxy-phenyl)-1 H-benzoimidazole-5-carboxylic acid was solubilized in ⁇ , ⁇ -dimethylformamide at a 0.1 M concentration with 2 equivalents of diisopropylethylamine.
• the coupling reagent O-(Benzotriazol-1 -yl)-N,N,N',N'- tetramethyluronium tetrafluoroborate (TBTU) was solubilized at 0.1 M in N,N- dimethylformamide.
• Phenethylamine was solubilized in ⁇ , ⁇ -dimethylformamide at 0.1 M.
• Step 3 3-Methyl-3H-imidazole-4-carboxylic acid [4-(5-benzoyl-1 H-benzoimidazol- 2-yl)-phenyl]-amide
• Step 7 4-(5-Methyl-[1 ,3,4]oxadiazol-2-ylamino)-benzoic acid ethyl ester
• Step 3 ⁇ 2-[4-(5-Methyl-[1 ,3,4]oxadiazol-2-ylamino)-phenyl]-1 H-benzoimidazol-5- yl ⁇ -phenyl-methanone
• Step 7 4-Pyrimidin-2-yl-benzene-1 ,2-diamine xiif
• 2-Pyridin-4-yl-5-pyrimidin-2-yl-1 H-benzoimidazole was synthesized from 4- Pyrimidin-2-yl-benzene-1 ,2-diamine xiif and pyridine-4-carbaldehyde by following the procedure for example 1 .
• 2-(4-Piperidin-1 -yl-phenyl)-1 H- benzoimidazole-5-carbonitrile was prepared from 3,4-diamino-benzonitrile xiic and 4-Piperidin-1 -yl-benzaldehyde by following the procedure for example 1 .
• reaction mass was filtered through celite® bed, the filtrate was concentrated under reduced pressure to obtain a crude product as a brown solid which was further purified by washing with methanol to get 2-(4-amino-phenyl)-1 H-benzoimidazole-5-carbonitrile as a reddish brown solid (320 mg, 72 % yield). MS m/z (M+H) 234.9.
• Step 3 1 -Methyl-1 H-pyrrole-2-carboxylic acid [4-(5-cyano-1 H-benzoimidazol-2-yl)- phenyl]-amide
• reaction mixture from above was added to crushed ice, filtered and the solid obtained from above was purified by column chromatography using silica gel 230-400 in CH 2 CI 2 / methanol solvent system.
• the product obtained was further purified by recrystallization from methanol to obtain 1 -methyl-1 H-pyrrole-2-carboxylic acid [4- (5-cyano-1 H-benzoinnidazol-2-yl)-phenyl]-annide as an off white solid (95 mg, 16 % yield).
• N-[4-(5-Cyano-1 H-benzoimidazol-2-yl)-phenyl]-4-methoxy-benzamide was prepared from 4-methoxybenzoic acid and 2-(4-amino-phenyl)-1 H- benzoimidazole-5-carbonitrile by following the procedure for example 34.
• Step 3 Furan-3-carboxylic acid [4-(5-trifluoromethyl-1 H-benzoimidazol-2-yl)- phenyl]-amide
• Furan-3-carboxylic acid [4-(5-trifluoromethyl-1 H-benzoimidazol-2-yl)-phenyl]-amide was synthesized from 4-[5-(trifluoromethyl)-1 H-benzoimidazol-2-yl]aniline and furan-3-carboxylic acid by following the procedure for example 13.
• 5-nitro-2-(pyridin-4-yl)-1 H-benzoimidazole was synthesized from 4-nitro-benzene- 1 ,2-diamine xiig and pyridine-4-carbaldehyde by following the procedure for example 1 .
• Step 3 Furan-3-carboxylic acid (2-pyridin-4-yl-1 H-benzoimidazol-5-yl)-amide Furan-3-carboxylic acid (2-pyridin-4-yl-1 H-benzoimidazol-5-yl)-amide was synthesized using 2-(pyridin-4-yl)-1 H-benzoimidazol-5-amine and furan-3- carboxylic acid by following the procedure for example 13.
• N'-[4-(4,6-Dimethyl-1 H-benzoimidazol-2-yl)-phenyl]-N,N-dimethyl-ethane-1 ,2- diamine was synthesized from 3, 5-dimethyl-benzene-1 ,2-diamine xiid and 4-(2- dimethylamino-ethylamino)-benzaldehyde by following the procedure for example 1 .
• 6-chloro-4-methyl-2-(4-nitrophenyl)-1 H-benzoimidazole was synthesized from 5- chloro-3-methyl-benzene-1 ,2-diamine xiie and 4-nitro benzaldehyde by following the procedure for example 1 .
• Step 3 Furan-3-carboxylic acid [4-(6-chloro-4-methyl-1 H-benzoimidazol-2-yl)- phenyl]-amide
• Furan-3-carboxylic acid [4-(6-chloro-4-methyl-1 H-benzoimidazol-2-yl)-phenyl]- amide was synthesized from 4-(6-chloro-4-methyl-1 H-benzoimidazol-2-yl)aniline and furan-3-carboxylic acid by following the procedure for example 13.
• Furan-2-yl-[4-(1 H-imidazo[4,5-c]pyridin-2-yl)-phenyl]-methanone was synthesized from 4-(furan-2-carbonyl)-benzoic acid and pyridine-3,4-diamine by following the procedure for example 26.
• 2-(4-Dimethylamino-phenyl)-1 H-benzoimidazole-5-carboxylic acid phenyl amide was synthesized from 2-(4-dimethylamino-phenyl)-1 H-benzoimidazole-5- carboxylic acid and aniline by following the procedure for example 1 .
• 2-(4-dimethylamino-phenyl)-1 H-benzoimidazole-5-carboxylic acid (3-chloro- phenyl)-amide was synthesized from 2-(4-dimethylamino-phenyl)-1 H- benzoimidazole-5-carboxylic acid and 3-chloro-phenylamine by following the procedure for example 1 .
• the following components were used: an antibody directed against the His-tag, labelled with the donor fluorophore (Europium cryptate); The streptavidine protein, labelled with the acceptor XL665 fluorophore directed against the biotin. All the components except Erk1 , Erk2 and the peptide were purchased from Cisbio (Condolet, France).
• HTRF Homogeneous Time Resolved Fluorescence assay combines two techniques: Fluorescence Resonance Energy Transfer (FRET) and Time Resolved (TR) measurement.
• FRET Fluorescence Resonance Energy Transfer
• TR-FRET a transfer of fluorescence between a donor and an acceptor molecule generates a signal that can then be measured. This energy transfer is only possible when both fluorophores are close enough to each other. Therefore, this method can be used to detect protein-protein interaction.
• the reaction medium contained: 6xHis-ERK1 at 7.5 nM, biotin-MyD88peptide at 25 nM, anti-Histidine-Cryptate antibody at 1 .3325 nM and XL665 labeled-Streptavidine at 3.125 nM.
• the reaction medium contained: GST-ERK2 at 50 nM, biotin-MyD88pep at 50 nM, anti-GST-Cryptate antibody at 0.8 nM and XL665 labeled-Streptavidine at 12.5 nM.
• Concentrations of compounds to be tested ranged from 0.1 ⁇ to 100 ⁇ .
• Stock solutions of compounds according to the invention were prepared at 10 mM in DMSO.
• Compounds stock solution were directly distributed in black 384-well plate (Greiner low-volume) in Tris-HCI 20 mM, pH 8/0.1 % BSA/0.05% Tween 20/150mM NaCI (ERK1 assay) or in Tris-HCI 10 mM, pH8/0.1 % BSA/0.05% Tween 20/150mM NaCI (ERK2 assay) by an HP D300 Digital Dispenser to obtain the required final concentrations. Proteins (ERK1 , ERK2) were then added and the plate was incubated for 30 min at room temperature.
• biotin- Myd88peptide, anti-his-K, anti-GST-k and XL665-Streptavidin were added to each corresponding well to reach a final volume of 20 ⁇ _.
• the plate was incubated at room temperature for 2 hours and fluorescence was measured using a TECAN Infinite F500 Reader®.
• Results are calculated as the variation of fluorescence (Delta F) between control and samples.
• SRE promoter refer to "Serum response elements", which is a DNA sequence (CC(A/T)6GG) that is used upstream of reporter genes and is known to be the binding site of the SRF (Serum response factor) proteins encoded by SRF gene identified by Gene Bank number (Gene ID: 6722, NM_003131 .2).
• HCT1 16 Human Colon Tumor (HCT1 16) p53+/+ cell line stably transformed to express the luciferase reporter gene under the control of the serum response element (SRE) was used.
• This cell line was cultured in McCoy's medium supplemented with 10% FBS, 2 mM glutamine, 1 % antibiotics and 1 ⁇ of puromycin.
• HCT1 16 p53+/+ SRE luciferase cells were plated in 96-well flat-bottom plate at 20,000/well and incubated at 37°C for 36 hours. The medium was discarded and replaced by 100 ⁇ of serum free medium for 16 hours. Cells were then pretreated for 2 hours with the compounds according to the invention at various concentrations (from 0.001 ⁇ to 80 ⁇ ). Cells were then stimulated by addition of 10% FCS and incubated at 37°C for four additional hours and the expression of reporter gene was assessed using the One-Glo Luciferase reagent (Promega). Luminescence was quantified after 5 minutes in a TECAN infinite M200 Reader (Mannedorf, Switzerland). The results are presented below at paragraph 2-5.
• HCT1 16 cells were subcutaneously injected into the flank of 6-week-old female Swiss-nude mice (Charles River, Les Oncins, France). When tumors reached 100 mm 3 , mice were treated intraperitoneally daily with 50, 25, 12,5 mg/kg of compound 6, or a vehicle. Tumor volume was measured twice a week with an electronic caliper. The results are presented on figure 4. 2-5/ Results

Landscapes

• Chemical & Material Sciences (AREA)
• Organic Chemistry (AREA)
• Health & Medical Sciences (AREA)
• General Health & Medical Sciences (AREA)
• Veterinary Medicine (AREA)
• Public Health (AREA)
• Medicinal Chemistry (AREA)
• Pharmacology & Pharmacy (AREA)
• Life Sciences & Earth Sciences (AREA)
• Animal Behavior & Ethology (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• General Chemical & Material Sciences (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Epidemiology (AREA)
• Engineering & Computer Science (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Hematology (AREA)
• Oncology (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Plural Heterocyclic Compounds (AREA)
• Nitrogen Condensed Heterocyclic Rings (AREA)
• Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Priority Applications (7)

Applications Claiming Priority (2)

Related Child Applications (2)

Publications (3)

Family

ID=57113229

Family Applications (1)

Country Status (7)

Cited By (3)

Families Citing this family (2)

Citations (9)

Family Cites Families (7)

• 2017
  • 2017-09-20 ES ES17769091T patent/ES2973850T3/es active Active
  • 2017-09-20 US US16/334,513 patent/US11384081B2/en active Active
  • 2017-09-20 CA CA3037424A patent/CA3037424A1/en active Pending
  • 2017-09-20 CN CN201780070287.7A patent/CN110234640B/zh active Active
  • 2017-09-20 WO PCT/EP2017/073801 patent/WO2018054989A1/en not_active Ceased
  • 2017-09-20 EP EP17769091.4A patent/EP3515904B1/en active Active
  • 2017-09-20 JP JP2019515523A patent/JP7278945B2/ja active Active
• 2022
  • 2022-06-03 US US17/831,592 patent/US12509465B2/en active Active

Patent Citations (9)

Non-Patent Citations (8)

Also Published As

Similar Documents

Legal Events